Afinitor — CareFirst (Caremark)
Hormone receptor-positive, HER2-negative recurrent unresectable, advanced, or metastatic breast cancer (in combination with exemestane, fulvestrant, or tamoxifen)
Initial criteria
- Patient has hormone receptor (HR)-positive, HER2-negative recurrent unresectable, advanced, or metastatic breast cancer
- Requested medication will be used in combination with exemestane, fulvestrant, or tamoxifen
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months